XenoPort's (XNPT) XP-829 Efficacy 'Looks Good' - RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St gains as AI earnings lift tech, inflation data supports rate-hold bets
- Oil prices dip as investors weigh lower demand forecasts against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
RBC Capital Defends XenoPort (XNPT); Analyst Notes M&A Potential
September 15, 2015 1:30 PM EDTRBC Capital analyst Michael J. Yee defended XenoPort (NASDAQ: XNPT) amid weakness following the release of '829 data, saying shares are close to a floor, while noting potential M&A.
"Psoriasis data shows clear efficacy as we expected but undifferentiated GI side effects vs other fumarates and CELG Otezla. But if the market cap is $315M now and there is at least theoretical $200-300M + of takeout value on Horizant ($4-5/share), then Horizant could be cheap or '829 is... More
Further Development of XenoPort (XNPT) '829 is Unwarranted, Cowen Says
September 15, 2015 11:10 AM EDTCowen analyst Eric Schmidt reiterated an Market Perform rating on XenoPort (NASDAQ: XNPT) noting the XP23829 was active in the latest data but "unimpressive."
Schmidt commented, "XenoPort released Phase II data on '829 (a prodrug of monomethyl fumarate) for the treatment of moderate... More
XenoPort (XNPT) Announces Significant Prelim. Top-Line Data from XP23829 Phase 2 in Psoriasis
September 15, 2015 6:34 AM EDTXenoPort (NASDAQ: XNPT) announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. XP23829 met its primary endpoint in both 800 mg once daily and 400 mg twice daily doses, demonstrating statistically significant improvements in percent change from baseline to week 12 in Psoriasis Area and Severity Index (PASI) score. XP23829 is a patented prodrug of monomethyl fumarate (MMF) in a novel oral formulation that was designed to potentially offer physicians and patients an effective, better tolerated and easier to use therapeutic option to currently... More
